TICKERNERD
Menu
WVEWVEHealthcare · Biotechnology

WVE Stock Forecast: Wave Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.59
−1.71% on the day

The 17 Wall Street analysts covering Wave Life Sciences, Inc. hold a median 12-month price target of $15 — +226.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$904.5M
Ticker Nerd rank
14 / 100
Median analyst target
$15
Analysts covering
17
Revenue$2.3M−73.9% y/y
Operating income−$73.8M
Net income−$69.4M
Free cash flow−$54.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−9.1%
YTD
−73.0%
1Y
−35.9%
From 52W high
−78.5%
From 52W low
0.0%
$5
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WVE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Wave Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
52
Size
46
Value
43
Revisions
43
Accruals
31
Growth
31
Momentum
16
Volatility
14
Issuance
14

Quality (52): The business earns solid, repeatable profits on what it owns.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WVE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WVE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26WVEHigh $42Median $15Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $10Median $15High $42

The green dot is the last close — the median target sits +226.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
4 Aug 2026MizuhoMaintainsOutperform$27 → $23
31 July 2026B. Riley SecuritiesMaintainsBuy$31 → $22
31 July 2026CitigroupMaintainsBuy$24 → $19
31 July 2026WedbushMaintainsOutperform$15 → $12
20 May 2026Wells FargoMaintainsOverweight—
20 May 2026Wells FargoMaintainsOverweight$13 → $14
19 May 2026HC Wainwright & Co.MaintainsBuy$18 → $13
19 May 2026HC Wainwright & Co.MaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
30 Apr 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026Truist SecuritiesMaintainsBuy—
14 Apr 2026HC Wainwright & Co.MaintainsBuy—
27 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Wells FargoMaintainsOverweight—
25 Mar 2026MizuhoMaintainsOutperform—
10 Mar 2026Canaccord GenuityMaintainsBuy—
6 Mar 2026WedbushMaintainsOutperform—
2 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Feb 2026Wells FargoMaintainsOverweight—
5 Feb 2026Cantor FitzgeraldMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WVE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

WVE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Wave Life Sciences, Inc. returned −35.9% against +17.5% for the S&P 500, dividends included.

WVE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Oct 25Jan 26Apr 26Jul 26WVES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WVE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Wave Life Sciences, Inc. (WVE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.8×

Cheaper than 88% of US stocks

Price / sales
13.8×

Cheaper than 12% of US stocks

Price / book
1.7×

Cheaper than 52% of US stocks

EV / EBITDA
−2.1×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−73.9%

Higher than 3% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3248.3%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−67.4%

Higher than 18% of US stocks

Return on assets
−33.6%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Wave Life Sciences, Inc. (WVE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Wave Life Sciences, Inc. has a market value of $904.5M and an enterprise value of $457.4M.

  • Revenue in the twelve months to 30 June 2026: $65.4M. The latest quarter shrank 73.9% year on year.

  • Net income over the same four quarters: −$202.5M, a −309.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.09.

  • Free cash flow in the twelve months to 30 June 2026: −$193.1M.

  • Shares outstanding: 193.3M.

  • Trailing P/E: −3.8×; forward P/E: −4.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Wave Life Sciences, Inc. employs 317 people — $206K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

WVE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
WVEWave Life Sciences, Inc.$904.5M
14
LXRXLexicon Pharmaceuticals, Inc.$889.9M
68
OLMAOlema Pharmaceuticals, Inc.$890.7M
30
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
ARDXArdelyx, Inc.$869.8M
50
GERNGeron Corp.$864.7M
52
IMMXImmix Biopharma, Inc.$864.2M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Wave Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WVE news & analysis

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Wave Life Sciences Ltd. announced it will present at the Cantor 2026 Global Healthcare Conference, based in Cambridge, Mass. The company communicated the scheduled presentation via a press release dated September 03, 2026.

Why it matters — Presenting at a major healthcare conference gives Wave Life Sciences a platform to update investors and industry participants on its pipeline and business, which WVE watchers may monitor for visibility and engagement.

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

24/7 Wall Street · 13 Aug 2026neutral

A 24/7 Wall Street article describes Wave Life Sciences as a potential $1 billion RNA-medicine acquisition target, noting its stock trades near its 52-week low of $5.01, well below its 52-week high of $21.73.

Why it matters — WVE watchers would care because the article highlights the company as a possible takeover target in the RNA-medicine space, which could influence investor perception of the stock's value.

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Seeking Alpha · 11 Aug 2026neutral

Wave Life Sciences Ltd. presented at the Bank of America SMID Cap Virtual Conference, with a transcript of its presentation published by Seeking Alpha. The item indicates the company participated in the investor conference and its remarks were made available.

Why it matters — A WVE watcher would follow this because conference presentations give an official forum for the company to communicate its business to investors and analysts.

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

GlobeNewsWire · 10 Aug 2026neutral

Wave Life Sciences has completed its redomiciliation process, changing its parent company from a Singapore entity to a Delaware corporation via a statutory scheme of arrangement under Singapore's Companies Act.

Why it matters — The redomiciliation to Delaware may affect Wave's corporate governance, regulatory filings, and legal structure, which is relevant for investors tracking the company's operational and jurisdictional changes.

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

GlobeNewsWire · 5 Aug 2026neutral

Wave Life Sciences Ltd. announced the expected completion date for its previously announced redomiciliation to Delaware. The company stated this in a press release issued from Cambridge, Mass. on August 5, 2026.

Why it matters — A WVE watcher would care because the redomiciliation changes the company's corporate structure and legal jurisdiction, which affects governance and where the company is incorporated.

FAQ

Frequently asked questions about WVE stock

What is the WVE stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Wave Life Sciences, Inc. have a median 12-month price target of $15, with estimates ranging from $10 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WVE stock a buy right now?

Of the 17 analysts covering Wave Life Sciences, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Wave Life Sciences, Inc. 14 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WVE?

As at 12 Sept 2026, Wave Life Sciences, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (52 of 100).

Will WVE stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +226.8% from the last close, and Ticker Nerd's factor model ranks Wave Life Sciences, Inc. 14 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WVE stock forecast for 2030?

No analyst covering Wave Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WVE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $42 over the next 12 months.

How has WVE stock performed over the past year?

Wave Life Sciences, Inc. returned -35.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Wave Life Sciences, Inc. do?

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health.

What is the latest news on WVE?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference". Wave Life Sciences Ltd. announced it will present at the Cantor 2026 Global Healthcare Conference, based in Cambridge, Mass. The company communicated the scheduled presentation via a press release dated September 03, 2026.

Company

About Wave Life Sciences, Inc.

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.

CEO Dr. Paul B. Bolno M.B.A., M.D. · 317 employees · United States · https://wavelifesciences.com